BofA Reports 15% Ownership in Aptevo Therapeutics (APVO)

Rhea-AI Filing Summary

Schedule 13G shows Bank of America Corporation reports beneficial ownership of 494,341 shares of Aptevo Therapeutics Inc. common stock, representing 15.0% of the outstanding class based on 3,287,918 shares. The holdings are reported as shared voting and shared dispositive power for 494,341 shares; no sole voting or dispositive power is claimed. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Positive

• Material ownership: 494,341 shares equal 15.0%, a clearly reported, investor‑material stake
• Transparency: Ownership and voting/dispositive breakdowns are fully disclosed with a certification of ordinary‑course holdings

Negative

• None.

Insights

Equity Ownership Analyst

Bank of America holds a material minority stake (15%) with shared control.

The 15.0% position is large enough to be investor‑material and could influence market perception of Aptevo Therapeutics' shareholder base. Ownership is recorded as shared voting and shared dispositive power, which indicates coordinated voting/control arrangements rather than unilateral control.

This position is described as held in the ordinary course of business; monitor any later amendments or Schedule 13D filings for changes in intent or increases above 20.0% that could alter governance dynamics within the next 3–12 months.

Corporate Governance Specialist

Shared power signals influence potential but no sole control over corporate decisions.

Because sole voting and dispositive powers are listed as 0, the holder does not claim unilateral control, reducing immediate takeover or control-change concerns. The certification indicates the stake is not intended to change control.

Investors should watch subsequent disclosures for any nominee filings, coordinated group statements, or proxy activity that would appear in routine corporate governance filings over the next proxy cycle.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aptevo Therapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03835L504

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03835L504

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 494,341.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 494,341.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

494,341.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The calculation of percentage owned is based on 3,287,918 outstanding shares referenced in the Form 10-Q filed with the SEC on August 11, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aptevo Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 2401 4TH AVE., SUITE 1050, SEATTLE, WASHINGTON, 98121.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: DELAWARE
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 03835L504
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 494,341.00
(b)	Percent of class: 15.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 494,341.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 494,341.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); and Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Andres Ortiz
Name/Title:	Authorized Signatory
Date:	10/06/2025

FAQ

How many Aptevo Therapeutics (APVO) shares does Bank of America own?

Bank of America reports beneficial ownership of 494,341 shares.

What percentage of APVO does the reported stake represent?

The stake represents 15.0% of the outstanding common stock based on 3,287,918 shares.

Does Bank of America have sole voting control of the APVO shares?

No. The filing shows 0 shares with sole voting power and 494,341 shares with shared voting power.

Is the stake reported as intended to change control of Aptevo (APVO)?

The certifying statement indicates the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Which Bank of America entities are associated with this Schedule 13G filing?

The filing is by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc. and Bank of America N.A..